JPH3

JPH3 (junctophilin-3) is best characterized in the available corpus through the pathogenic consequences of a CTG/CAG repeat expansion at its locus, which causes Huntington's disease-like 2 (HDL2) (PMID:21555070). In a BAC transgenic mouse model recapitulating the human disease, a promoter at the JPH3 locus drives an antisense CAG repeat transcript encoding an expanded polyglutamine protein; this antisense polyQ product is a primary driver of toxicity, since silencing the sense CUG transcript does not prevent polyQ-containing nuclear inclusions, and these inclusions sequester CBP to interfere with CBP-mediated transcriptional activation (PMID:21555070). The expanded sense r(CUG) repeat folds into a hairpin bearing periodic 1×1 UU internal loops that sequester RNA-binding proteins, defining a structured RNA element targetable by small molecules [PMID:bio_10.1101_2024.06.21.600119]. Beyond the repeat-expansion disease mechanism, the canonical JPH3 protein acts as a tumor suppressor in colorectal and gastric cancers, where its expression raises cytosolic Ca2+, induces ER-stress and unfolded protein response genes, activates calpain, and triggers mitochondrial depolarization and apoptosis, while promoter CpG methylation silences it in these cancers (PMID:28656064). In a context-dependent contrast, JPH3 is upregulated in anaplastic thyroid cancer and functions there as an oncogene driving proliferation, invasion, migration, and cisplatin resistance through COL26A1-mediated JAK-STAT activation (PMID:41862190).

1. 2011 High

   Established that HDL2 toxicity is driven not only by the expanded repeat in the JPH3 sense transcript but primarily by an antisense CAG-derived polyglutamine protein that sequesters CBP, reframing the disease as a bidirectional repeat-expansion disorder.

   Evidence BAC transgenic mouse model with genetic silencing of the CUG transcript, polyQ nuclear inclusion immunohistochemistry, and CBP sequestration assays validated against patient tissue

   PMID:21555070

   Open questions at the time

   • Does not define the normal physiological function of the canonical JPH3 protein
   • Mechanism by which CBP sequestration alters specific transcriptional programs not resolved
   • Relative contribution of CUG RNA toxicity versus polyQ protein toxicity not fully quantified
2. 2016 Low

   Mapped the proteome-level consequences of JPH3 expansion in human HDL2 brain, showing convergence with Huntington's disease pathways and implicating shared downstream cellular dysfunction.

   Evidence Quantitative SILAC-like proteomics of post-mortem cortex with Western blot validation and pathway enrichment

   PMID:27486686

   Open questions at the time

   • Pathway-level association does not establish direct JPH3 protein mechanism
   • No functional follow-up linking altered proteins to JPH3 loss or polyQ gain
   • Cannot distinguish cause from consequence in end-stage disease tissue
3. 2017 Medium

   Defined a tumor-suppressor function for the canonical JPH3 protein in digestive cancers, linking it to Ca2+ signaling, ER stress, calpain activation, and mitochondrial apoptosis, and showing epigenetic silencing in tumors.

   Evidence Ectopic expression in colorectal/gastric cancer lines, xenografts, Ca2+ and mitochondrial membrane potential measurements, calpain and ER-stress assays, and bisulfite sequencing

   PMID:28656064

   Open questions at the time

   • Direct molecular target through which JPH3 modulates cytosolic Ca2+ not identified
   • Single-lab study without reciprocal genetic loss-of-function validation
   • Relationship to JPH3 membrane-anchoring activity not established
4. 2024 Medium

   Provided atomic-level structures of the r(CUG) repeat hairpin from the JPH3 locus and its small-molecule binding mode, establishing the structured RNA element responsible for RNA-binding-protein sequestration as a druggable target.

   Evidence NMR spectroscopy with restrained molecular dynamics of r(CUG) bound to three small molecules (preprint)

   PMID:bio_10.1101_2024.06.21.600119

   Open questions at the time

   • Addresses the RNA product of the locus rather than the JPH3 protein
   • Preprint not yet peer-reviewed
   • In-cell efficacy and selectivity of the small molecules not demonstrated
5. 2026 Low

   Revealed a context-dependent oncogenic role for JPH3 in anaplastic thyroid cancer, contrasting its tumor-suppressor role in digestive cancers, acting through COL26A1-driven JAK-STAT signaling.

   Evidence Expression analysis, in vitro proliferation/invasion/migration assays, xenografts, JAK-STAT activation and cisplatin resistance assays in ATC cells

   PMID:41862190

   Open questions at the time

   • No direct biochemical evidence linking JPH3 to COL26A1 or JAK-STAT
   • Single-lab, single-study finding without reconstitution
   • Mechanistic basis for opposite roles in different cancers unexplained

• The normal physiological function of the canonical JPH3 protein and how it reconciles its membrane-anchoring/Ca2+ role with opposing roles across cancer contexts remains unresolved.
• No structural or biochemical characterization of the JPH3 protein itself in the corpus
• Direct molecular partners of the canonical protein not defined
• Mechanism reconciling tumor-suppressor versus oncogenic roles unknown